CANBRIDGE PHARM.DL-00001 (MF1) — Working Capital to Net Assets Ratio
CANBRIDGE PHARM.DL-00001 (MF1) has a Working Capital to Net Assets ratio of 101.0% as of December 2025. Working capital of €-345.17 Million (current assets of €110.17 Million minus current liabilities of €455.34 Million) is measured against net assets of €-341.75 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See MF1 days of operational coverage to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
CANBRIDGE PHARM.DL-00001 Working Capital to Net Assets (2021–2025)
This chart shows how CANBRIDGE PHARM.DL-00001's Working Capital to Net Assets ratio has evolved across 5 annual periods from 2021 to 2025. As of December 2025, the ratio stands at 101.0%, reflecting working capital of €-345.17 Million against net assets of €-341.75 Million EUR. For the complete balance sheet picture, see MF1 asset base.
Annual Working Capital to Net Assets for CANBRIDGE PHARM.DL-00001 (2021–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for CANBRIDGE PHARM.DL-00001 from 2021 to 2025, covering 5 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Read MF1 current and long-term liabilities for a breakdown of total debt and financial obligations.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 101.0% | €-345.17 Million | €-341.75 Million | €110.17 Million | €455.34 Million | ▲ +8.8 pp |
| 2024 | 92.2% | €-437.26 Million | €-474.49 Million | €45.35 Million | €482.61 Million | ▼ -204.6 pp |
| 2023 | 296.8% | €-118.08 Million | €-39.79 Million | €209.86 Million | €327.94 Million | ▲ +223.2 pp |
| 2022 | 73.6% | €227.06 Million | €308.56 Million | €505.16 Million | €278.11 Million | ▼ -16.7 pp |
| 2021 | 90.3% | €625.93 Million | €693.39 Million | €811.71 Million | €185.78 Million | — |